Overall rank by patents
#5,380
of 50,000 tracked assignees
USPTO PatentsView assignee record - 64 granted patents across 10 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
The verdict
According to USPTO PatentsView, Medshine ranks #5,380 of 50,000 tracked US assignees by granted-patent volume, with 64 patents across 10 technology areas.
Medshine Discovery Inc. has been granted 64 US utility patents between 2017 and 2025, placing Medshine Discovery Inc. at #5,380 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a Foreign Corporation, Medshine Discovery Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Medshine sits between MC10, Inc. (64 patents, rank #5,377) and Narrative Science Llc (64 patents, rank #5,385) - the closest US assignees by grant volume. The composite Innovation Score of 45.9/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 49 grants, compared with 10 in the 2015–2019 window, a +390% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Medshine Discovery Inc.'s 18.3 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 10 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
MC10, INC.
64 patents
MECHOSHADE SYSTEMS, LLC
64 patents
MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
64 patents
MITEK SYSTEMS, INC.
64 patents
Meritor Heavy Vehicle Braking Systems (UK) Limited
64 patents
Mid-West Metal Products Company, Inc.
64 patents
NISSHINBO HOLDINGS INC.
64 patents
Narrative Science LLC
64 patents
Medshine Discovery Inc.
64 patents
What this shows Medshine holds 64 patents at rank #5,381, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #5,381 in granted patent volume.
Other assignees with the most granted patents in Medshine's primary technology class.
Two PlainPatent-derived peer sets for Medshine, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (46 here).
Nearest assignees by average claims per patent (18.3 here).
Medshine's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 1.6% |
| 2018 | 3 | 4.7% |
| 2019 | 6 | 9.4% |
| 2020 | 7 | 10.9% |
| 2021 | 10 | 15.6% |
| 2022 | 17 | 26.6% |
| 2023 | 13 | 20.3% |
| 2024 | 2 | 3.1% |
| 2025partial year | 5 | 7.8% |
Top 10 of 10 technology areas
Historical grant data only; it does not rate legal strength or current strategy.
Overall rank by patents
#5,380
of 50,000 tracked assignees
45.9 out of 100
How to use this portfolio
Medshine's 64 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.